Opportunity Information: Apply for RFA HL 20 007
The National Institutes of Health (NIH) funding opportunity "Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial Not Allowed)" (RFA-HL-20-007) supports the creation of a coordinated set of research model systems that can reliably reproduce the key, disease-defining features of human idiopathic pulmonary fibrosis (IPF). IPF is a progressive, fatal lung disease, and a major bottleneck in the field has been the limited ability of existing models to capture what actually happens in people across the full course of the disease. This program is designed to fill that gap by encouraging multiple, complementary models rather than relying on a single approach, with the goal of better representing IPF biology from earliest onset through progression.
The core purpose of the award is to advance understanding of IPF pathogenesis by developing and refining models that mirror essential aspects of the human condition. In practical terms, that means generating experimental systems that can illuminate mechanisms driving fibrosis initiation, persistence, and worsening over time, and that can be used to test hypotheses about why scarring develops and becomes irreversible. Because the emphasis is on a "collection" of models, the intent is that different platforms can cover different parts of the disease puzzle, such as cellular interactions, tissue remodeling, immune contributions, aging-related processes, genetic susceptibility, and other factors that define IPF. The models supported through this initiative are also intended to be useful beyond the original awardee teams, functioning as a broader resource that other researchers can adopt for mechanistic studies and for preclinical development and evaluation of potential therapies.
This opportunity uses the U01 cooperative agreement mechanism, which typically indicates substantial NIH program involvement compared with a standard research project grant. The activity category is Health, with CFDA number 93.838, and the sponsoring agency is NIH. The funding instrument being a cooperative agreement suggests that funded teams should expect active coordination, milestones, and collaboration consistent with building shared, high-value research resources rather than purely independent investigator-driven projects. Clinical trials are not allowed under this announcement, meaning the supported work should focus on model development and preclinical or foundational research rather than testing interventions in human participants as a formal clinical trial.
A wide range of applicant organizations are eligible. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofit organizations (both with and without 501(c)(3) status, excluding institutions of higher education in those categories as specified); for-profit organizations other than small businesses; small businesses; and other applicant types. The announcement also explicitly highlights additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. Foreign institutions (non-U.S. entities applying as the primary applicant) are not eligible to apply; however, non-domestic components of U.S. organizations are eligible, and foreign components are allowed as defined in the NIH Grants Policy Statement, which typically means foreign collaborators or parts of the project conducted abroad may be permissible under NIH rules when appropriately justified.
Key administrative details provided in the source include an original closing date of 2019-10-01 and a creation date of 2019-06-04. The award ceiling and expected number of awards are not specified in the provided listing, so applicants would normally consult the full NIH funding opportunity announcement and related NIH notices for budget expectations, project period norms, and any caps or limits. Overall, the program is aimed at strengthening the IPF research ecosystem by producing better, more faithful disease models that can accelerate discovery and de-risk therapy development for a disease with high unmet medical need.Apply for RFA HL 20 007
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838.
- This funding opportunity was created on 2019-06-04.
- Applicants must submit their applications by 2019-10-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The opportunity is titled "Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial Not Allowed)" with funding opportunity number RFA-HL-20-007.
Which agency is sponsoring this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
What is the main goal of this program?
The goal is to create a coordinated set (a collection) of research model systems that can reliably reproduce key, disease-defining features of human idiopathic pulmonary fibrosis (IPF), improving how well models reflect what happens in people from early onset through disease progression.
Why is NIH supporting new IPF research models through this program?
A major bottleneck in IPF research has been that existing models often fail to capture what actually happens in humans across the full course of the disease. This initiative is intended to address that gap by advancing and refining models that mirror essential aspects of the human condition.
What disease area does this opportunity focus on?
This opportunity focuses on idiopathic pulmonary fibrosis (IPF), described as a progressive, fatal lung disease with high unmet medical need.
What types of research are supported under this opportunity?
The supported work centers on developing and refining experimental model systems to illuminate IPF pathogenesis, including mechanisms that drive fibrosis initiation, persistence, and worsening over time, and to test hypotheses about why scarring develops and becomes irreversible.
Does this program require a single model approach or multiple model approaches?
The program encourages multiple, complementary models rather than relying on a single approach. The intent is for different platforms to cover different parts of the IPF disease puzzle.
What aspects of IPF biology are these models expected to help represent?
Models are intended to help represent IPF biology from earliest onset through progression and may address areas such as cellular interactions, tissue remodeling, immune contributions, aging-related processes, genetic susceptibility, and other defining factors of IPF.
How are the models expected to be used beyond the awardee teams?
The models are intended to function as a broader resource that other researchers can adopt for mechanistic studies and for preclinical development and evaluation of potential therapies.
What funding mechanism is used for this opportunity?
This opportunity uses the U01 cooperative agreement mechanism.
What does a U01 cooperative agreement imply about NIH involvement?
A cooperative agreement typically indicates substantial NIH program involvement compared with a standard research project grant. Funded teams should expect active coordination, milestones, and collaboration consistent with building shared, high-value research resources.
Are clinical trials allowed under this funding opportunity?
No. The announcement specifies "Clinical Trial Not Allowed," meaning the supported work should focus on model development and preclinical or foundational research rather than testing interventions in human participants as a formal clinical trial.
What is the activity category for this opportunity?
The activity category is Health.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.838.
Which organizations are eligible to apply?
A wide range of organizations are eligible, including state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofit organizations (with and without 501(c)(3) status, excluding institutions of higher education in those nonprofit categories as specified); for-profit organizations other than small businesses; small businesses; and other applicant types.
Are minority-serving and mission-specific institutions explicitly included in the eligible applicant types?
Yes. The listing highlights eligibility for Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based or community-based organizations eligible to apply?
Yes. Faith-based or community-based organizations are explicitly highlighted among eligible groups.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are included among the eligible applicant types.
Are foreign (non-U.S.) institutions eligible to apply as the primary applicant?
No. Foreign institutions (non-U.S. entities applying as the primary applicant) are not eligible to apply.
Can a U.S. organization include foreign components in the proposed work?
Yes. Non-domestic components of U.S. organizations are eligible, and foreign components are allowed as defined in the NIH Grants Policy Statement (for example, foreign collaborators or parts of the project conducted abroad may be permissible when appropriately justified under NIH rules).
What are the key administrative dates mentioned in the listing?
The listing provides a creation date of 2019-06-04 and an original closing date of 2019-10-01.
Is the award ceiling provided in the information shown?
No. The award ceiling is not specified in the provided listing.
Is the expected number of awards provided in the information shown?
No. The expected number of awards is not specified in the provided listing.
Where should applicants look for budget expectations, project period norms, or any caps?
Because the award ceiling and expected number of awards are not specified in the provided listing, applicants would typically consult the full NIH funding opportunity announcement and related NIH notices for budget expectations, project period norms, and any caps or limits.
What is the intended overall impact of this program on the IPF research ecosystem?
The program is aimed at strengthening IPF research by producing better, more faithful disease models that can accelerate discovery and de-risk therapy development for a disease with high unmet medical need.
Browse more opportunities from the same category: Health
Next opportunity: Renewal - Integrated Food Safety System Online Research and Collaboration Development (U18) Clinical Trials Not Allowed
Previous opportunity: Drug Screening with Biofabricated 3-D Skin Disease Tissue Models (U18 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 20 007
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 20 007) also looked into and applied for these:
| Funding Opportunity |
|---|
| Interpersonal Processes in Alzheimer's Disease and Related Dementias Clinical Interactions and Care Partnerships (R01 Clinical Trial Optional) Apply for RFA AG 20 006 Funding Number: RFA AG 20 006 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Cardiovascular Developmental Biology Data Resource Center (U01 - Clinical Trial Not Allowed) Apply for RFA HL 20 017 Funding Number: RFA HL 20 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Biology of Aging in Reproductive Tissues (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 036 Funding Number: RFA AG 20 036 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Pediatric Cardiac Genomics Consortium (U01 - Clinical Trial Not Allowed) Apply for RFA HL 20 015 Funding Number: RFA HL 20 015 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Diversity Program Consortium Dissemination and Translation Awards (U01 - Clinical Trial Not Allowed) Apply for RFA RM 19 003 Funding Number: RFA RM 19 003 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed) Apply for PAR 19 296 Funding Number: PAR 19 296 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Research to Understand and Inform Interventions that Promote the Research Careers of Individuals in the Biomedical Sciences (R01 - Clinical Trial Not Allowed) Apply for PAR 19 295 Funding Number: PAR 19 295 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional) Apply for PAR 19 297 Funding Number: PAR 19 297 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Aging, Driving and Early Detection of Dementia (R01 Clinical Trial Optional) Apply for RFA AG 20 022 Funding Number: RFA AG 20 022 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Limited Competition: Continuation of the Center for Genomic Studies on Mental Disorders (U24 Clinical Trial Not Allowed) Apply for RFA MH 20 215 Funding Number: RFA MH 20 215 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanistic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 Clinical Trial Not Allowed) Apply for RFA NS 19 039 Funding Number: RFA NS 19 039 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Characterization of Marmosets as Models of Aging and Age-Related Diseases (U34 Clinical Trial Not Allowed) Apply for RFA AG 20 007 Funding Number: RFA AG 20 007 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Non-Invasive Neurostimulation in AD/ADRD (R01 Clinical Trial Optional) Apply for PAR 19 298 Funding Number: PAR 19 298 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Institute of General Medical Sciences (NIGMS) Bridges to the Baccalaureate (T34) Apply for PAR 19 299 Funding Number: PAR 19 299 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Country Health Information Systems and Data Use (CHISU) Apply for 7200AA19R00065 Funding Number: 7200AA19R00065 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| National Institute of General Medical Sciences (NIGMS) Bridges to the Doctorate (T32) Apply for PAR 19 300 Funding Number: PAR 19 300 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Centers for Cryoelectron Tomography (U24 - Clinical Trial Not Allowed) Apply for RFA RM 19 009 Funding Number: RFA RM 19 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Network Hub for Cryoelectron Tomography (U24 - Clinical Trial Not Allowed) Apply for RFA RM 19 010 Funding Number: RFA RM 19 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lipid Signaling in Healthspan and Longevity Regulation (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 039 Funding Number: RFA AG 20 039 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) Apply for PAR 19 302 Funding Number: PAR 19 302 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 20 007", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.